Brilacidin: complete guide

Brilacidin is an investigational host defense peptide mimetic, not a true peptide. This guide covers its structure, mechanism, Phase 2 trials, side effects and status.

Complete guide5 min read

Key takeaway

Brilacidin is a nonpeptide arylamide with a molecular weight of 936.9 g/mol. In a Phase 2 trial of mucositis in head and neck cancer, severe mucositis occurred in 43% on brilacidin and 60% on placebo. A Phase 2 COVID-19 trial in 120 patients did not meet its primary endpoint.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“Brilacidin is not approved by the FDA for any use.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited4 in this article · 4 across 1 article on Brilacidin
Related productsBPC-157, TB-500 and thymic peptides

Brilacidin is a synthetic molecule built to copy the germ-killing shape of the body’s host defense peptides. It is not itself a peptide. This guide covers its structure, mechanism, trials, reported side effects and status. Sources were checked on November 17, 2026.

Quick answer: Brilacidin, also called PMX-30063, is a host defense peptide mimetic from Innovation Pharmaceuticals. It disrupts bacterial membranes in lab studies. Phase 2 trials tested it in skin infections, radiation-induced mucositis and COVID-19. It is not FDA-approved, and no trial has been active since 2021.

Vitrapep does not sell brilacidin; this page is a reference summary of published research and regulatory information.

What is brilacidin?

Brilacidin is a small molecule designed to act like an antimicrobial peptide. A 2024 paper calls it a “synthetic small-molecule nonpeptide mimetic” and an arylamide (Larwood & Stevens, 2024). An arylamide is built from ring-shaped aromatic units joined by amide bonds, not from amino acids.

Its developer, Innovation Pharmaceuticals, describes it as a “de novo-designed” and “synthetic, non-peptidic, small molecule” modeled on host defense proteins (Innovation Pharmaceuticals, 2026). So brilacidin belongs on a peptide reference list as a mimic, not a true peptide. Our primer on what peptides are explains the difference. Natural host defense peptides include LL-37.

PubChem lists the formula as C40H50F6N14O6 and the molecular weight as 936.9 g/mol (PubChem CID 25023695). Its research code is PMX30063 (Mensa et al., 2014).

Table 1

Brilacidin: key facts

Fact Detail
Structure type Synthetic nonpeptide arylamide (peptide mimetic)
Class Host defense peptide (defensin) mimetic
Molecular formula C40H50F6N14O6
Molecular weight 936.9 g/mol
Development stage Phase 2 completed (last trial completed 2021); no active registered trial
Sponsor or developer Innovation Pharmaceuticals; earlier trials sponsored by Cellceutix and PolyMedix

How does brilacidin work?

Brilacidin targets microbial membranes, much like natural host defense peptides. A lab study in Staphylococcus aureus found that “brilacidin causes membrane depolarization” to an extent comparable to daptomycin (Mensa et al., 2014). Depolarization means the membrane loses its electrical charge.

Gene activity profiles in the same study “mostly indicates abrogation of cell wall and membrane functions.” The authors also suggested that protein misfolding stress inside the cell may contribute. These are bacterial lab data. The developer also reports immune-modulating activity, which this page does not assess.

What is brilacidin being studied for?

Brilacidin is not approved by the FDA for any use. ClinicalTrials.gov lists five completed studies under its two names.

  • acute bacterial skin and skin structure infections, Phase 2, PolyMedix (NCT01211470, completed 2012);
  • serious skin infections, Phase 2, Cellceutix, 215 enrolled (NCT02052388, completed 2014);
  • radiation-induced mucositis of the mouth in head and neck cancer, Phase 2 (NCT02324335, completed 2017);
  • a Phase 1 release study in healthy volunteers (NCT04240223, completed 2020); and
  • hospitalized adults with COVID-19, Phase 2 (NCT04784897, completed 2021).

The developer says it has completed an End-of-Phase 2 meeting with FDA on the mucositis program. It describes the antifungal work as preclinical (Innovation Pharmaceuticals, 2026). No new registered trial has started since 2021.

What did the key trials show?

Mucositis in head and neck cancer. This randomized, quadruple-masked human trial compared brilacidin with placebo in patients receiving chemoradiation. Posted results count severe mucositis (WHO grade 3 or 4) in the efficacy group. It occurred in 9 of 21 brilacidin patients (43%) and 15 of 25 placebo patients (60%). No p-value is posted (NCT02324335).

COVID-19. This randomized, placebo-controlled human trial enrolled 120 hospitalized adults. Everyone also received standard care. Sustained recovery through Day 29 occurred in 93.2% and 87.5% of the two brilacidin arms, against 90.0% on placebo. Neither comparison was significant (p = 0.73 and p = 0.60) (NCT04784897). The developer states the primary endpoint “was not met.”

Skin infections. The 215-person Phase 2 skin infection trial has no results on ClinicalTrials.gov. We found no peer-reviewed paper reporting it.

What side effects have studies reported?

In the mucositis trial, serious adverse events occurred in 8 of 29 brilacidin patients and 5 of 30 placebo patients. There were no deaths. Common events included fatigue (21 on brilacidin vs 13 on placebo) and taste change (17 vs 13). Others were dry mouth (16 vs 9) and constipation (13 vs 17). These patients were also receiving cancer chemoradiation, which causes many of the same effects.

In the COVID-19 trial, serious adverse events occurred in 7 of 60 patients on brilacidin and 7 of 60 on placebo. Deaths were 4 in each group. Any treatment-emergent adverse event occurred in 53 of 60 and 39 of 60, respectively.

What is brilacidin’s regulatory status, and how is it used in research?

Brilacidin is an investigational compound. Its developer says it holds FDA Qualified Infectious Disease Product (QIDP) designation and Fast Track designations. It says the mucositis trial ran under Fast Track, and that COVID-19 also received Fast Track (Innovation Pharmaceuticals, 2026). We did not find these on an fda.gov page. We found no FDA warning about brilacidin.

Academic labs now study brilacidin mostly against fungi and viruses. One study found it boosted caspofungin against several pathogenic fungi in lab tests and in mouse infection models (dos Reis et al., 2023). Another reported activity against SARS-CoV-2 in human lung and monkey cell lines (Bakovic et al., 2021).

Frequently asked questions about brilacidin

Is brilacidin a peptide?

No. It is a nonpeptide arylamide that mimics the shape and charge of host defense peptides.

Is brilacidin FDA-approved?

No. It has been tested only in clinical trials, and none is currently active.

What is PMX-30063?

It is the original research code for brilacidin, used by PolyMedix and in early papers.

How is brilacidin similar to daptomycin?

Both depolarize the membrane of S. aureus in lab tests. Daptomycin is an approved lipopeptide antibiotic; brilacidin is an unapproved mimetic.

Did brilacidin work for COVID-19?

Its Phase 2 trial did not meet its primary endpoint of time to sustained recovery through Day 29.

What to know now

  • Structure: nonpeptide arylamide peptide mimetic; C40H50F6N14O6; 936.9 g/mol.
  • Mechanism: depolarizes bacterial membranes in lab studies, comparable to daptomycin.
  • Evidence: severe mucositis 43% vs 60% in a small Phase 2; COVID-19 Phase 2 missed its primary endpoint.
  • Safety: serious events 8 of 29 vs 5 of 30 in the mucositis trial; 7 of 60 in each COVID-19 group.
  • Status: not FDA-approved; no registered trial since 2021.

What we’re watching

Any new ClinicalTrials.gov entry for brilacidin, such as the Phase 3 mucositis trial the developer has discussed. Peer-reviewed reports of the completed skin infection and mucositis trials. Related guides: LTX-315 and murepavadin.

More for immune system

All 24 compounds for immune system

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 25023695, brilacidin; Larwood 2024, Antibiotics, 13; Mensa 2014, Antimicrobial Agents and Chemotherapy, 58; Innovation Pharmaceuticals 2026, Brilacidin; Innovation Pharmaceuticals 2014; Innovation Pharmaceuticals 2021; Cellceutix Corporation 2014, Efficacy and safety study of brilacidin to treat serious skin infections; PolyMedix 2010; Innovation Pharmaceuticals 2020; dos Reis 2023, Nature Communications, 14; Bakovic 2021, Viruses, 13. All 11 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 25023695, brilacidin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/25023695
  2. Larwood, D. J., & Stevens, D. A. (2024). Antifungal activity of brilacidin, a nonpeptide host defense molecule. Antibiotics, 13(5), 405. https://doi.org/10.3390/antibiotics13050405
  3. Mensa, B., et al. (2014). Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrobial Agents and Chemotherapy, 58(9), 5136-5145. https://doi.org/10.1128/AAC.02955-14
  4. Innovation Pharmaceuticals. (2026). Brilacidin. Retrieved November 17, 2026, from https://ipharminc.com/brilacidin-1
  5. Innovation Pharmaceuticals, Inc. (2014). Study of the effects of brilacidin oral rinse on radiation-induced oral mucositis in patients with head and neck cancer (ClinicalTrials.gov ID NCT02324335). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02324335
  6. Innovation Pharmaceuticals, Inc. (2021). A study to evaluate the efficacy and safety of brilacidin in hospitalized participants with COVID-19 (ClinicalTrials.gov ID NCT04784897). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04784897
  7. Cellceutix Corporation. (2014). Efficacy and safety study of brilacidin to treat serious skin infections (ClinicalTrials.gov ID NCT02052388). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02052388
  8. PolyMedix, Inc. (2010). Initial treatment for acute bacterial skin infections (ABSSSI) caused by Staphylococcus aureus (ClinicalTrials.gov ID NCT01211470). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01211470
  9. Innovation Pharmaceuticals, Inc. (2020). A study to investigate the use of delayed release tablets for colonic delivery of brilacidin in healthy volunteers (ClinicalTrials.gov ID NCT04240223). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04240223
  10. dos Reis, T. F., et al. (2023). A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi. Nature Communications, 14(1), 2052. https://doi.org/10.1038/s41467-023-37573-y
  11. Bakovic, A., et al. (2021). Brilacidin demonstrates inhibition of SARS-CoV-2 in cell culture. Viruses, 13(2), 271. https://doi.org/10.3390/v13020271